nach oben

Erschienen in:

26.11.2021 | Case Report

Epstein-Barr virus-related lymphoproliferative disorders in T-cell repleted haploidentical transplantation with post-transplant cyclophosphamide

verfasst von: Vedat Uygun, Nazan Özsan, Hayriye Daloğlu, Seda Öztürkmen, Koray Yalçın, Gülsün Karasu, Akif Yeşilipek

Erschienen in: International Journal of Hematology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

EBV-associated lymphoproliferative disorders (LPDs) are common in hematopoietic stem cell transplantation (HSCT) with T-cell-depleted grafts, but are extremely rare in HSCT patients with T-cell-replete grafts with post-transplant cyclophosphamide (PTCy). Here we present the cases of two pediatric patients who developed EBV-related LPD after T-cell-replete haplo-HSCT with PTCy. One of these is the first reported case of EBV-positive mucocutaneous ulcer (EBVMCU) developing after PTCy. EBV-related diseases are rare in T-cell-replete haplo-HSCT patients with PTCy. However, in patients with risk factors, it is reasonable to screen for EBV viremia for LPD.

Styczynski J, Van der Velden W, Fox CP, Engelhard D, De La Camara R, Cordonnier C et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7): 803–11

Kanakry JA, Kasamon YL, Bolanos-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, et al. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013;19(10):1514–7. https://doi.org/10.1016/j.bbmt.2013.07.013.CrossRefPubMedPubMedCentral

Terao T, Tsushima T, Fukumoto A, Kuzume A, Miura D, Narita K, et al. EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide. Int J Hematol. 2021;114:136–40. https://doi.org/10.1007/s12185-021-03111-z.CrossRefPubMed

Uygun V, Karasu G, Daloglu H, Ozturkmen S, Caki Kilic S, Hazar V, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: a single-center study. Pediatr Transplant. 2019;23(7): e13546. https://doi.org/10.1111/petr.13546.CrossRefPubMed

Fujimoto A, Suzuki R. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation: pathogenesis, risk factors and clinical outcomes. Cancers (Basel). 2020;12(2):328. https://doi.org/10.3390/cancers12020328.CrossRefPubMedCentral

Salas MQ, Prem S, Remberger M, Lam W, Kim DDH, Michelis FV, et al. High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. Leuk Lymphoma. 2020;61(13):3198–208. https://doi.org/10.1080/10428194.2020.1797010.CrossRefPubMed

Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, et al. Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(7):1441–9. https://doi.org/10.1016/j.bbmt.2019.02.016.CrossRefPubMed

Retiere C, Willem C, Guillaume T, Vie H, Gautreau-Rolland L, Scotet E, et al. Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Oncotarget. 2018;9(14):11451–64. https://doi.org/10.18632/oncotarget.24328.CrossRefPubMedPubMedCentral

Hickey CL, Romee R, Nikiforow S, Dorfman D, Mazzeo M, Koreth J. A case of Epstein Barr virus-related post-transplant lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide. Haematologica. 2020;105(7):e379–81. https://doi.org/10.3324/haematol.2019.236067.CrossRefPubMedPubMedCentral

10.

DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA. Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2017;23(3):498–504. https://doi.org/10.1016/j.bbmt.2016.12.628.CrossRefPubMed

11.

Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20(11):1711–6. https://doi.org/10.1016/j.bbmt.2014.06.028.CrossRefPubMed

12.

Giaimo MPL, Cambò B, Palma BD, Falcioni F. EBV-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient: a difficult diagnosis. Arch Clin Gastroenterol. 2021;7(1):011–4.

13.

Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer–a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34(3):405–17. https://doi.org/10.1097/PAS.0b013e3181cf8622.CrossRefPubMedPubMedCentral

14.

Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B. Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. Bone Marrow Transplant. 2016;51(2):300–2. https://doi.org/10.1038/bmt.2015.245.CrossRefPubMed

15.

Ashrafi F, Shahidi S, Ebrahimi Z, Mortazavi M. Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series. Int J Hematol Oncol Stem Cell Res. 2015;9(1):26–32.PubMedPubMedCentral

16.

Cullis B, D’Souza R, McCullagh P, Harries S, Nicholls A, Lee R, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis. 2006;47(5):e67-72. https://doi.org/10.1053/j.ajkd.2006.01.029.CrossRefPubMed

17.

Sinit RB, Horan KL, Dorer RK, Aboulafia DM. Epstein-barr virus-positive mucocutaneous ulcer: case report and review of the first 100 published cases. Clin Lymphoma Myeloma Leuk. 2019;19(2):e81–92. https://doi.org/10.1016/j.clml.2018.10.003.CrossRefPubMed

Titel: Epstein-Barr virus-related lymphoproliferative disorders in T-cell repleted haploidentical transplantation with post-transplant cyclophosphamide
verfasst von: Vedat Uygun
Nazan Özsan
Hayriye Daloğlu
Seda Öztürkmen
Koray Yalçın
Gülsün Karasu
Akif Yeşilipek
Publikationsdatum: 26.11.2021
Verlag: Springer Singapore
Erschienen in: International Journal of Hematology / Ausgabe 4/2022
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-021-03267-8

Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution

Original Article

Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation

Original Article

Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies

Original Article

Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome

Case Report

The acidic domain of Hmga2 and the domain’s linker region are critical for driving self-renewal of hematopoietic stem cell

Original Article

Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group

Original Article

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

10.01.2025
Mammakarzinom
Nachrichten

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

10.01.2025
Antiemetische Therapie
Nachrichten

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

08.01.2025
Mammakarzinom
Nachrichten

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

08.01.2025
Non-Hodgkin-Lymphome
Nachrichten

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Epstein-Barr virus-related lymphoproliferative disorders in T-cell repleted haploidentical transplantation with post-transplant cyclophosphamide

Abstract

Weitere Artikel der Ausgabe 4/2022

Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution

Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation

Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies

Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing–Neel syndrome

The acidic domain of Hmga2 and the domain’s linker region are critical for driving self-renewal of hematopoietic stem cell

Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Veränderung der Brustdichte beeinflusst das Krebsrisiko

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten